photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer Clinical Trials

Clinical Trial with Votrient for Advanced NETs

Votrient (pazopanib) is a drug-agent of GlaxoSmithKline that appears to work through targeting angiogenesis and growth pathways, and has been approved for use in renal cell carcinoma and advanced soft tissue sarcoma. Two other recent targeted agents that have been approved by the U.S. FDA for the treatment of neuroendocrine tumors are everolimus and sunitinib. […]

Share Button

A Set-back for ARBs for the Treatment of Pancreatic Cancer?

Again, for more than a decade there have been theoretical discussions about the use of drugs commonly used to treat high blood pressure for use in the treatment of cancer – pancreatic cancer. And having just published a Pancreatica blog entry based on the pre-clinical study and work by Jain and colleagues from Harvard on […]

Share Button

Nanoliposomal Topoisomerase I Inhibitor for Advanced Cancer of the Pancreas

There is no universally agreed upon second line treatment for metastatic pancreatic cancer. On August 20 in the British Journal of Cancer, the results of an interesting international Phase II clinic trial using nanoliposomal irinotecan for the treatment of earlier pre-treated metastatic pancreatic cancer were published. The researchers included Dr. Margaret Tempero, who is on […]

Share Button
Page 4 of 512345